news – Kinnov Therapeutics

European and US addiction KOLs provide their insight on AUD and KT-110 (video)

Lucas Biela — Wed, 30 Oct 2024 14:36:03 +0000

In a 11-min video, five experts in addiction explain why KT-110 is a game changer and why it is a hope for millions of AUD patients.

https://www.kinnov-therapeutics.com/wp-content/uploads/2024/05/kinnov-KT110.mp4

Henri-Jean Aubin is Professor of Psychiatry and Addictology at Hôpital Pitié-Salpétrière in Paris, France. He was the Principal Investigator in KT-110 phase 2 trial.

Karl Mann is Professor Emeritus at Central Institute of Mental Health, University of Heidelberg, Germany.

Wim van den Brink is Professor Emeritus of Psychiatry and Addiction at Academic Medical Center, University of Amsterdam, The Netherlands.

Antoni Gual is Head of the Addictions Unit Neurosciences Institute at University of Barcelona, Spain.

Raymond Anton is Professor Emeritus of Psychiatry and Addictions at Medical University of South Carolina, USA.

Kinnov Therapeutics was present at the 37th ECNP Congress

Lucas Biela — Wed, 30 Oct 2024 14:13:19 +0000

Kinnov Therapeutics was present at the 37th ECNP congress https://www.ecnp.eu/congress2024/ECNPcongress, in Milan 21-24 Sep, 2024.

Within the scope of ECNP’s New Medications Symposium, Prof Henri-Jean Aubin and Julien Guiraud were invited to present results of phase 2 clinical trials.

The annual ECNP Congress is Europe’s premier scientific meeting for disease-oriented brain research.

Prof Henri-Jean Aubin was Principal Investigator for phase 2 clinical trial.

Julien Guiraud (Vergio Consulting) is co-author of phase 2 clinical trial publication.

Our phase II results published in Addiction journal !

kinnov — Fri, 26 Apr 2024 08:41:39 +0000

We are thrilled to announce our ground breaking Phase II results published in Addiction Journal (April 10th 2024) entitled:

Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trial.
https://onlinelibrary.wiley.com/doi/10.1111/add.16484

The article demonstrates the positive results of Kinnov Therapeutics phase II trial in the reduction of total alcohol consumption in patients with severe alcohol use disorder.

Addiction is the official and reference journal of the Society for the Study of Addiction, and has been in publication since 1884. It publishes peer-reviewed research reports on pharmalogical and behavioural addictions, bringing together research conducted within many different disciplines.

New galenic form accepted for evaluation on patients

kinnov — Fri, 19 Apr 2024 10:29:58 +0000

Kinnov Therapeutics (KT) meets a new important milestone in galenic. To overcome the difficult observance of alcoholic patients, KT has developed and patented an innovative galenic form allowing a single daily intake of KT-110. This major challenge to deliver two active molecules with different PK and pharmacological profiles, has been met allowing application to ANSM* for evaluation of the new galenic on patients. The dossier has been accepted in March triggering the assays on the new formula on 8 patients. Results are expected for June 2024.

*ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) is the French Drug Regulatory Authority.

Outsourcing-Pharma shares article providing insights as to why KT-110 is fresh hope for heavy drinkers

kinnov — Wed, 08 Nov 2023 15:08:59 +0000

Through review of Kinnov phase 2 trial results, and interview with Henri-Jean Aubin, Alain Puech and Emmanuel de Rivoire, Outsourcing-Pharma shares an article providing key answers as to why people affected with AUD could see their alcohol intake reduced by half in three months thanks to Kinnov therapeutics’s KT-110:

https://www.outsourcing-pharma.com/Article/2023/11/07/Fresh-hope-for-heavy-drinkers-thanks-to-Kinnov-Therapeutics

Outsourcing-Pharma has been the leading online news source for the pharma industry for more than 16 years.

For Kinnov phase 2 trial, Henri-Jean Aubin is the coordinating investigator, Alain Puech is the medical director, and Emmanuel de Rivoire is the managing director of Kinnov Therapeutics.

European Commission shares results of Kinnov projects funded by their Horizon 2020 grant

kinnov — Wed, 08 Nov 2023 15:06:37 +0000

CORDIS platform shares results of Kinnov projects funded by European Commission within the scope of the Horizon 2020 program:

https://cordis.europa.eu/project/id/873252/reporting/fr

CORDIS is the main source of results of European Commission’s innovation and research funding programs.
Horizon 2020 is the funding program granted to Kinnov in 2019 for their projects on alcohol use disorders (Cocktail phase 2 study and bilayer development).
Within the scope of this funding program, covering the period between October 2019 and March 2022, Kinnov kept EU regularly informed about status of activities through periodic reporting. Reporting shared by CORDIS is the third and last one, updating EU on period from September 2021 to March 2022.

Kinnov Therapeutics will be present at the 29th annual BIO-Europe

kinnov — Mon, 30 Oct 2023 09:20:29 +0000

Kinnov Therapeutics will be present at the 29th annual BIO-Europe

Kinnov Therapeutics will be present at the 29th annual BIO-Europe congress BIO-Europe | Meet dealmakers from biotech, pharma and finance (informaconnect.com), in Munich on November 6, 7 and 8, 2023.

This Congress is industry’s largest gathering of biopharma professionals in Europe.

Through one-to-one meetings, Kinnov Therapeutics will have the opportunity to meet future partners for its alcohol use disorder program.

Alcohol dependency: in a phase 2 clinical trial, a combination of drugs gave a better results than current medications [article in French]…

kinnov — Tue, 28 Jun 2022 07:24:03 +0000

A phase 2 trial based on the simultaneous blockade of two neurobiological pathways has shown exciting results in patients with severe alcohol use disorder.

Actualités Medscape, 23 juin 2022

Alcooldépendance : dans un essai de phase 2, une combinaison fait mieux que les médicaments actuels

kinnov — Tue, 28 Jun 2022 07:22:49 +0000

Un essai de phase 2 reposant sur le blocage simultané de deux voies neurobiologiques a obtenu des résultats enthousiasmants chez des patients atteints d’un trouble sévère de l’usage de l’alcool.

Actualités Medscape, 23 juin 2022

Kinnov Therapeutics Announces Positive Phase 2 Outcome: Key Milestone with Lead Drug KT-110 for Alcohol Use Disorder

kinnov — Thu, 09 Jun 2022 15:40:29 +0000

Kinnov-Therapeutics Announces Positive Phase 2 Outcome: Key Milestone with Lead Drug KT-110 for Alcohol Use Disorder.

Kinnov-Therapeutics has reached a key clinical milestone for treatment of Alcohol Use Disorder with a Phase 2 clinical study for its game changing drug KT-110. Alcoholism is a major public health issue with a strong unmet medical need.

Link to online article